Eli Lilly and Company $LLY Shares Sold by Jag Capital Management LLC

Jag Capital Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 44.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,570 shares of the company’s stock after selling 11,047 shares during the quarter. Eli Lilly and Company comprises about 1.1% of Jag Capital Management LLC’s holdings, making the stock its 28th biggest holding. Jag Capital Management LLC’s holdings in Eli Lilly and Company were worth $10,354,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in LLY. Sumitomo Mitsui Financial Group Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $29,000. Steph & Co. boosted its stake in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc raised its position in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,042.68 on Wednesday. The stock has a market capitalization of $983.62 billion, a price-to-earnings ratio of 45.43, a PEG ratio of 1.23 and a beta of 0.39. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company’s 50-day simple moving average is $1,054.49 and its 200-day simple moving average is $923.72. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period last year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo’s next‑gen CagriSema failed to match Lilly’s tirzepatide, reinforcing Lilly’s clinical leadership and market share prospects. Novo’s stumbles burnish Lilly’s widening lead
• Positive Sentiment: Product/label expansion: FDA cleared a multi‑dose KwikPen for Zepbound (tirzepatide), sold at the same self‑pay price — a convenience/retention strategy that supports prescriptions and stickiness. Zepbound KwikPen press release
• Positive Sentiment: Analyst support: Goldman Sachs and other firms continue to view Lilly as a top obesity/diabetes play, reiterating buy ratings and high price targets, which underpins investor confidence. TipRanks analyst note
• Neutral Sentiment: Retention push: Lilly is promoting the multi‑dose pen as a way to improve patient retention vs. single‑use devices — operationally positive but longer‑term for revenue impact. Invezz: multi-dose pen strategy
• Negative Sentiment: Price‑cut shock: Novo announced U.S. list prices for Ozempic/Wegovy will be halved (~$675/mo) starting 2027 — the prospect of steeper pricing competition prompted a pullback in LLY shares amid fears of margin/volume shifts across the class. Eli Lilly slips on Novo Nordisk price cut plans
• Negative Sentiment: Investor concern: Commentary flagged that aggressive pricing by Novo could change market dynamics and potentially impact Lilly’s revenue trajectory, creating near‑term uncertainty despite Lilly’s strong positioning. Fool: Why Eli Lilly Stock Slumped

Analysts Set New Price Targets

A number of brokerages recently weighed in on LLY. National Bank Financial set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a report on Monday, February 9th. Truist Financial set a $1,281.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Bank of America cut their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,229.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.